• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Chemically Programmed Antibody Is a Long-Lasting and Potent Inhibitor of Influenza Neuraminidase

tetano

Editor, Senior Moderator
Chembiochem. 2012 Sep 10. doi: 10.1002/cbic.201200439. [Epub ahead of print]
A Chemically Programmed Antibody Is a Long-Lasting and Potent Inhibitor of Influenza Neuraminidase.
Hayakawa M, Toda N, Carrillo N, Thornburg NJ, Crowe JE Jr, Barbas CF 3rd.
Source

Departments of Chemistry, Molecular Biology, and, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 (USA).
Abstract

Programming an anti-flu strategy: A new and potent neuraminidase inhibitor that maintains long-term systemic exposure of an antibody and the therapeutic activity of the neuraminadase inhibitor zanamivir has been created. This strategy could provide a promising new class of influenza A drugs for therapy and prophylaxis, and validates enzyme inhibitors as programming agents in synthetic immunology.

Copyright ? 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

PMID:
22965667
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22965667
 
Back
Top Bottom